Back to top
more

Health Catalyst (HCAT)

(Delayed Data from NSDQ)

$7.70 USD

7.70
388,823

-0.07 (-0.90%)

Updated Nov 1, 2024 04:00 PM ET

After-Market: $7.64 -0.06 (-0.78%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.10%
2Buy17.80%
3Hold9.50%
4Sell2.70%
5Strong Sell2.70%
S&P50011.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value B Growth C Momentum C VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 25% (62 out of 251)

Industry: Medical Info Systems

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Health Catalyst (HCAT) Upgraded to Buy: Here's What You Should Know

by Zacks Equity Research

Health Catalyst (HCAT) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).

Health Catalyst (HCAT) Q2 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Health Catalyst (HCAT) give insight into how the company performed in the quarter ended June 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Health Catalyst (HCAT) Tops Q2 Earnings and Revenue Estimates

by Zacks Equity Research

Health Catalyst (HCAT) delivered earnings and revenue surprises of 33.33% and 1.21%, respectively, for the quarter ended June 2024. Do the numbers hold clues to what lies ahead for the stock?

Sanghamitra Saha headshot

Time to Play 5 Top-Ranked Stocks With Rising P/E?

by Sanghamitra Saha

Tap five stocks with increasing P/E ratios to try out an out-of-the-box approach. These stocks include AMC Entertainment (AMC), Exagen (XGN), Health Catalyst (HCAT), CLEAR Secure (YOU) and Applied DNA Sciences (APDN).

Do Options Traders Know Something About Health Catalyst (HCAT) Stock We Don't?

by Zacks Equity Research

Investors need to pay close attention to Health Catalyst (HCAT) stock based on the movements in the options market lately.

Zacks Industry Outlook Highlights Hims & Hers Health, Enovis Corp and Health Catalyst

by Zacks Equity Research

Hims & Hers Health, Enovis Corp and Health Catalyst are part of the Zacks Industry Outlook article.

Urmimala Biswas headshot

3 Medical Info Systems Stocks to Buy as GenAI Transforms Healthcare

by Urmimala Biswas

Zacks Medical Info Systems industry stocks like Hims & Hers Health (HIMS), Enovis Corporation (ENOV) and Health Catalyst (HCAT) are expected to gain from the GenAI wave.

Why Health Catalyst (HCAT) Might be Well Poised for a Surge

by Zacks Equity Research

Health Catalyst (HCAT) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

Wall Street Analysts See a 75.19% Upside in Health Catalyst (HCAT): Can the Stock Really Move This High?

by Zacks Equity Research

The average of price targets set by Wall Street analysts indicates a potential upside of 75.2% in Health Catalyst (HCAT). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Health Catalyst (HCAT) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates

by Zacks Equity Research

The headline numbers for Health Catalyst (HCAT) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Health Catalyst (HCAT) Q1 Earnings Beat Estimates

by Zacks Equity Research

Health Catalyst (HCAT) delivered earnings and revenue surprises of 66.67% and 0.11%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Sonendo, Inc. (SONX) Reports Q1 Loss, Tops Revenue Estimates

by Zacks Equity Research

Sonendo (SONX) delivered earnings and revenue surprises of -244.44% and 11.86%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Health Catalyst (HCAT) Q1 Earnings on the Horizon: Analysts' Insights on Key Performance Measures

by Zacks Equity Research

Get a deeper insight into the potential performance of Health Catalyst (HCAT) for the quarter ended March 2024 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.

Definitive Healthcare Corp. (DH) Matches Q1 Earnings Estimates

by Zacks Equity Research

Definitive Healthcare (DH) delivered earnings and revenue surprises of 0% and 0.81%, respectively, for the quarter ended March 2024. Do the numbers hold clues to what lies ahead for the stock?

Premium Growth Propels Humana (HUM) to Easy Q1 Earnings Beat

by Zacks Equity Research

Humana (HUM) bumps up individual Medicare Advantage membership growth guidance.

Elevance (ELV) Q1 Earnings Beat on Rate Hikes, Guidance Raised

by Zacks Equity Research

Elevance Health (ELV) has a leftover capacity of around $3.6 billion under its share buyback authorization.

Acadia Healthcare (ACHC) Opens Facility to Address Mental Health

by Zacks Equity Research

Acadia Healthcare (ACHC) inaugurates an acute care hospital in Mesa, AZ, to cater to patients struggling with addiction and mental health issues in the area.

Brookdale Senior (BKD) Sees Y/Y Increase in Q1 Occupancy Levels

by Zacks Equity Research

Brookdale Senior (BKD) witnesses 29 straight months of year-over-year increases in weighted average occupancy level.

Down -24.71% in 4 Weeks, Here's Why You Should You Buy the Dip in Health Catalyst (HCAT)

by Zacks Equity Research

Health Catalyst (HCAT) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.

Compelling Reasons to Hold Acadia Healthcare (ACHC) Stock Now

by Zacks Equity Research

Growing commercial, Medicare and Medicaid revenues will likely boost Acadia Healthcare's (ACHC) top line.

Humana's (HUM) Medicaid Business Teams Up With CPESN USA in Ohio

by Zacks Equity Research

Humana's (HUM) partnership with CPESN USA in Ohio aims to overcome barriers like limited access to healthcare services in rural and underserved communities.

Select Medical (SEM) Expands in Florida With UF Health JV

by Zacks Equity Research

Select Medical (SEM) inks a joint venture agreement with UF Health Jacksonville to open a 48-bed inpatient rehabilitation hospital in Florida.

UnitedHealth's (UNH) Optum to Buy Steward's Physician Group

by Zacks Equity Research

UnitedHealth (UNH) unit Optum's acquisition of Steward Health's physician group is expected to close in the second quarter of 2024.

Wall Street Analysts Think Health Catalyst (HCAT) Could Surge 53.65%: Read This Before Placing a Bet

by Zacks Equity Research

The mean of analysts' price targets for Health Catalyst (HCAT) points to a 53.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Urmimala Biswas headshot

3 Medical Info Systems Stocks to Buy as Industry Improves

by Urmimala Biswas

A few Zacks Medical Info Systems industry stocks like Inspire Medical Systems (INSP), Talkspace (TALK) and Health Catalyst (HCAT) are expected to gain from the new normal trends.